The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04313634
Recruitment Status : Active, not recruiting
First Posted : March 18, 2020
Last Update Posted : March 27, 2024
Sponsor:
Information provided by (Responsible Party):
Sundeep Khosla, M.D., Mayo Clinic

Brief Summary:
To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.

Condition or disease Intervention/treatment Phase
Healthy Drug: Dasatinib Drug: Quercetin Drug: Fisetin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial.
Actual Study Start Date : June 9, 2020
Actual Primary Completion Date : June 6, 2023
Estimated Study Completion Date : June 6, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dasatinib plus Quercetin Treatment Goup
Subjects will receive Dasatinib (D; 100 mg for two days) plus Quercetin (Q; 1000 mg total daily for three consecutive days taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
Drug: Dasatinib
Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
Other Name: Sprycel

Drug: Quercetin
Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg

Experimental: Fisetin Treatment Group
Subjects will receive Fisetin (F; ~20 mg/kg/day for three consecutive days) taken orally on an intermittent schedule (starting every 28 days) with no-therapy periods in between dosing regimens, repeated every 28 days over 20 weeks, resulting in five total dosing periods throughout the entire intervention
Drug: Fisetin
Fisetin will be supplied in 100 mg capsules to be administered orally

No Intervention: Untreated Control Group
Subjects will not receive any intervention



Primary Outcome Measures :
  1. Percent Changes in C-terminal telopeptide of type I collagen [CTX] [ Time Frame: Baseline, 20 weeks ]
    Percent changes in serum bone turnover markers C-terminal telopeptide of type I collagen [CTX]


Secondary Outcome Measures :
  1. Percent changes in bone turnover markers [ Time Frame: Baseline, 4, 8, 12, 16, 20 weeks ]
    Percent Changes in amino-terminal propeptide of type I collagen [P1NP] and CTX

  2. BMD changes [ Time Frame: Baseline, 20 weeks ]
    Bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) at the lumbar spine, hip (total and femoral neck [FN]), and radius (total and ultra-distal).

  3. Plasma SASP factors [ Time Frame: Baseline, 4, 8, 12, 16, 20 weeks ]
    Plasma SASP factors



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Able and willing to provide informed consent.
  • Normal postmenopausal women
  • Aged ≥60 years

Exclusion Criteria:

  • Hemoglobin A1c ≥8.0% at screening
  • Subjects who are type II diabetic and on insulin
  • Abnormal screening labs: Calcium >10.1 mg/dL, Phosphorus >4.7 mg/dL, Thyroid stimulating hormone (TSH) level <0.3mU/L, Fasting blood glucose >200 mg/dL.
  • Presence of significant liver (total bilirubin, AST, ALT, or alkaline phosphatase >2x upper normal limit) or kidney disease (eGFR<30 ml/min/1.73 m2 (using the cystatin C blood levels for analysis). If any elevation were to be noted (2x the normal limit), the study participant would stop treatment and have levels re-drawn in a month, per the clinical judgement of the investigator
  • Presence of a clinical diagnosis of heart failure
  • Known active malignancy (including myeloma)
  • Current diagnosis of malabsorption or undergoing treatment for malabsorption disease
  • If any of the laboratory blood work drawn at the study visits return with lab values outside of the "normal limits" or show a significant change from a previous value, a repeat blood draw would be done before the subject is excluded.
  • Gastric bypass/reduction
  • Hyperthyroidism
  • Acromegaly
  • Cushing's syndrome
  • Hypopituitarism
  • Subjects with a fracture within the past six months
  • Undergoing treatment with any medications that affect bone turnover, including the following:

    • adrenocorticosteroids (> 3 months at any time or > 10 days within the previous yr, except for use of topical steroid creams or gels or inhaled steroids), anticonvulsant therapy (within the previous year), include only those taking Carbamazepine, Phenobarbital and Phenytoin,
    • bisphosphonates (within the past 3 yrs),
    • denosumab,
    • estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past yr)
  • QTc >450 msec
  • Inability to provide consent
  • Inability to tolerate oral medication
  • Current diagnosis of hypo- or hyperparathyroidism or currently undergoing treatment for the disease
  • Subjects on therapeutic doses of anti-coagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc)
  • Subjects with hypovitaminosis D (25-hydroxyvitamin D [25(OH)D] <20 ng/ml, whose level does not improve above 20 ng/ml after two courses of 4-week treatment of 50,000 IU/d of Vitamin D. They will be referred to their primary provider should this occur.
  • Subjects taking anti-arrhythmic medications known to cause QTc prolongation
  • Subjects taking potentially senolytic agents within the last 6 months: Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax
  • Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy
  • Subjects taking H2 antagonists, unless randomized to the control group
  • Tyrosine kinase inhibitor therapy
  • Subjects not having a PBTL p16INK4a mRNA expression level >95 percentile of young female controls (this cut-off is depicted by the dotted line in Fig. 6)
  • Known hypersensitivity or allergy to Dasatinib orQuercetin
  • Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin
  • If the DXA assessment reveals a spine or femur neck T-score < -2.5, the participant will be advised of this. She would then be given the option of withdrawing from the study to immediately start an osteoporosis drug through her primary care physician or continue in the study and defer osteoporosis drug treatment for the duration of the study (20 weeks). Given that osteoporosis is a chronic, long-term disease, the 20-week deferral would pose a minimal risk to the participant and she would be free to make this choice.
  • Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus). If antifungals are necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic.
  • Subjects taking strong inhibitors of CYP3A4
  • Subjects on antiplatelet agents (Clopidogrel [Plavix]; Dipyridamole + Asprin [Aggrenox]; Ticagrelor [Brilinta]; Prasugrel [Effient]; Ticlopidine [Ticlid] or Other) who are unable or unwilling to reduce or hold therapy prior to and during the study drug dosing periods. Subjects may continue their previous regimen between study drug dosing periods.
  • Subjects on quinolone antibiotic therapy for treatment or for prevention of infections within ten days.
  • Subjects taking proton pump inhibitors and unwilling to discontinue therapy for two days before and during the study drug dosing periods.
  • Subjects with clinically evident fluid retention
  • Subjects with evidence of right heart strain on ECG
  • Subjects with a history of pulmonary hypertension
  • Subjects with an abnormal Complete Blood Count (clinically insignificant changes would be acceptable based on the judgement of the investigators)
  • Presence of any condition the Investigator believes would place the subject at risk or would preclude the subject from successfully completing all aspects of the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04313634


Locations
Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Sundeep Khosla, M.D.
Investigators
Layout table for investigator information
Principal Investigator: Sundeep Khosla, MD Mayo Clinic
Additional Information:
Layout table for additonal information
Responsible Party: Sundeep Khosla, M.D., Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT04313634    
Other Study ID Numbers: 18-010546
First Posted: March 18, 2020    Key Record Dates
Last Update Posted: March 27, 2024
Last Verified: March 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dasatinib
Quercetin
Tyrosine Kinase Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antioxidants
Protective Agents
Physiological Effects of Drugs